Composition and method for treating the effects of diseases and maladies

ABSTRACT

An improved medicinal composition includes an effective amount of a pain relieving and anti-inflammatory pharmaceutical and an effective amount of a nutraceutical in a pharmaceutically acceptable base. At least one of the pharmaceutical and the nutraceutical treats a condition caused by an immune response of the respiratory system, particularly an immune response that triggers the cough reflex. The pharmaceutical is preferably a cough suppressant, an expectorant, or a decongestant. The nutraceutical is preferably an immune booster, an anti-oxidant, a liver protectant, a nutraceutical which sedates the cough reflex, or a combination thereof. Methods of using these compositions to treat conditions caused by a respiratory immune response are also disclosed.

This application claims the benefit of U.S. Provisional Application No.60/184,351 entitled “Composition and Method For Treating The Effects ofA Cold or Flu,” filed on Feb. 23, 2000.

FIELD OF THE INVENTION

The present invention relates to the field of medicinal compositions andmethods of using said compositions for treating diseases and maladies.In particular, the present invention relates to formulations comprisingcombinations of a pharmaceutical in combination with a nutraceutical,which when administered to a person in need thereof have the effect ofincreasing the beneficial effects of the pharmaceutical utilized.

BACKGROUND OF THE INVENTION

Beginning in prehistoric times, humans have attempted to treat everyknown type of illness and malady with naturally occurring products. Suchproducts were initially in their natural state, such as leaves, berries,roots, tree cuttings and extracts. With the advance of science, andgreater understanding of chemistry, humans have been able tosynthetically produce and extract a great variety of pharmaceuticalswhich were previously unknown or unidentified.

With the explosion of the pharmaceutical industry in the twentiethcentury, controversy quickly erupted between that industry, which reliedon the scientific results of its extensively tested products, and thenutraceutical industry, which had traditionally relied on less reputablesources, such as ancient herbals and verbal tradition, for itsauthority. Both sides have continued to develop separately due to mutualdistrust of each others' practices; the natural products community beingweary of the long term side-effects of man made drugs and thepharmaceutical industry disbelieving the value or efficacy of naturalremedies without hard scientific proof.

Recently, the scientific community has taken an increased interest indiscovering the various effects the ancient herbal remedies actuallyproduce. Extensive studies have been conducted into the efficacy of agreat number of these products and the results have largely beenpositive. As a result, consumers around the world have begun to takeinterest in these products due to the scientific data supporting thevalidity of their efficacy. But the greatest problem facing the averageconsumer of pharmaceuticals and natural remedies is the independence ofboth of these industries. It is often the case where a consumerpurchases a natural remedy and is unaware of a pharmaceuticalcounterpart or vice versa. Furthermore, the benefit to consumers ofproducts containing elements from both the nutraceutical andpharmaceutical industries could be great.

SUMMARY OF THE INVENTION

It is therefore an object of the present invention to provideformulations which combine the already know advantages of currently knowpharmaceuticals along with the newly discovered benefits ofnutraceuticals to produce an improved effect which not only treats acurrent ailment more effectively, but also functions to prevent therecurrence of illness.

It is a further object of the present invention to describe a method oftreating certain maladies with pharmaceuticals, previously used for suchmaladies, in conjunction with the newly discovered benefits ofnutraceuticals, in order to assist in the healing process as well aspreventing future maladies.

The foregoing objects and advantages of the invention are illustrativeof those that can be achieved by the present invention and are notintended to be exhaustive or limiting of the possible advantages whichcan be realized. Thus, these and other objects and advantages of theinvention will be apparent from the description herein or can be learnedfrom practicing the invention, both as embodied herein or as modified inview of any variation which may be apparent to those skilled in the art.Accordingly, the present invention resides in the novel methods,arrangements, combinations, compositions and improvements herein shownand described.

In accordance with these and other objects of the invention, a briefsummary of the present invention is presented. Some simplifications andomission may be made in the following summary, which is intended tohighlight and introduce some aspects of the present invention, but notto limit its scope. Detailed descriptions of preferred exemplaryembodiments adequate to allow those of ordinary skill in the art to makeand use the invention concepts will follow in later sections.

According to a broad aspect of the invention, there is disclosed acomposition for improving the efficacy of a pharmaceutical, which mayinclude selecting a pharmaceutical used for the treatment ofpredetermined symptoms of an ailment and/or the ailment itself, andselecting a nutraceutical, also used for treating said predeterminedsymptoms of an ailment and/or the ailment itself and combining into aformulation for treating the predetermined symptoms of an ailment or theailment itself.

In a further object of the invention, there is disclosed a method forimproving the efficacy of a pharmaceutical through the selection of apharmaceutical used for the treatment of predetermined symptoms of anailment and/or the ailment itself and selecting a nutraceutical which isalso used for treating said predetermined symptoms of an ailment and theailment itself. The pharmaceuticals and nutraceuticals are then combinedand formulated into solid, powder or liquid forms and administered to aperson in need thereof.

In the present invention, there are disclosed preparations for treatingthe symptoms of colds, flu, allergies, or sinus discomfort as well astreating pain and discomfort associated with heartburn, general bodyaches, headaches, migraines, menstruation, joint discomfort andarthritis, which may include pharmaceutical ingredients, preferablyselected from a group which includes, for example, acetaminophen,acetylsalicylic acid or an effective salt thereof, ibuprofen,ketoprofen, naproxen, naprosyn phenylpropanolamine bitartarate or aneffective salt thereof, pseudoephedrine hydrochloride or an effectivesalt thereof, diphenhydramine hydrochloride or an effective saltthereof, clemastine fumarate or an effective salt thereof,chlorpheniramine maleate or an effective salt thereof, bromopheniraminemaleate or an effective salt thereof, guaifenesin, dextromethorphanhydrochloride or an effective salt thereof, dextromethorphanhydrobromide or an effective salt thereof, famostidine, ranitidine,cimetidine, phenindamine tartarate or an effective salt thereof, calciumcarbonate or an effective salt thereof, and combinations thereof; andnutraceutical ingredients, preferably selected from the group whichincludes, for example, Echinacea purpurea, Echinacea angustifolia,Echinacea pillida, Gingko biloba, saw palmetto, ginseng, cat's claw (uñade gato), cayenne, bilberry, cranberry, grapeseed extract, St. john'swort, cascara sagrada, valerian, elderberry, elder flower, sweet elder,Sambucous nigra, Sambucous canadensis, garlic, Camellia sinensis,Camellia thea, Camellia theifera, Thea sinensis, Thea bohea, Theaviridis, goldenseal, wild cherry (Rosacea), quercetin, stinging nettles(Urtica), curcumin, bromelain, multiple pancreatic enzymes (protease,protease II, protease III, peptidase, amylase, lipase, cellulase,maltase, lactase, invertase), Emblica officinalis, eicosapentaenoicacid, docosahexaeonic acid, primrose oil, feverfew, ginger root, vitaminE (D-alpha-tocopherol), licorice root (Glycyrrhiza uralensis), aloevera, horseradish root, L-glutamine, ascorbic acid, antiscorbuticvitamin, rose hips, calcium ascorbate, cevitamic acid, citrusbioflavonoids complex, acerola, zinc or an effective salt thereof,Astragalus membranaceous, Astragalus mongolicus, membranous milk vetch,milk vetch, mongolian milk, dong quai, huangqi, hunag qi, moringa andcombinations thereof. Although these ingredients are preferred, otherpharmaceuticals and nutraceuticals may be substituted in their place.

According to another broad aspect of the invention, a method isdisclosed for treating the symptoms of colds, flu, allergies, or sinusdiscomfort as well as treating pain and discomfort associated withheartburn, general body aches, headaches, migraines, menstruation, jointdiscomfort and arthritis which includes formulating a composition whichmay include pharmaceutical ingredients preferably selected, for example,from a group which includes, acetaminophen, acetylsalicylic acid or aneffective salt thereof, ibuprofen, ketoprofen, naproxen, naprosynphenylpropanolamine bitartarate or an effective salt thereof,pseudoephedrine hydrochloride or an effective salt thereof,diphenhydramine hydrochloride or an effective salt thereof, clemastinefumarate or an effective salt thereof, chlorpheniramine maleate or aneffective salt thereof, bromopheniramine maleate or an effective saltthereof, guaifenesin, dextromethorphan hydrochloride or an effectivesalt thereof, dextromorphan hydrobromide or an effective salt thereof,famostidine, ranitidine, dimetidine, phenindamine tartarate or aneffective salt thereof, calcium carbonate or an effective salt thereof,and combinations thereof; and nutraceutical ingredients, preferablyselected, for example, from a group which includes, Echinacea purpurea,Echinacea angustifolia, Echinacea pillida, Gingko biloba, saw palmetto,ginseng, cat's claw (uña de gato), cayenne, bilberry, cranberry,grapeseed extract, St. john's wort, cascara sagrada, valerian,elderberry, elder flower, sweet elder, Sambucous nigra, Sambucouscanadensis, garlic, Camellia sinensis, Camellia thea, Camellia theifera,Thea sinensis, Thea bohea, Thea viridis, goldenseal, wild cherry(Rosacea), quercetin, stinging nettles (Urtica), curcumin, bromelain,multiple pancreatic enzymes (protease, protease II, protease III,peptidase, amylase, lipase, cellulase, maltase, lactase, invertase),Emblica officinalis, eicosapentaenoic acid, docosahexaeonic acid,primrose oil, feverfew, ginger root, vitamin E (D-alpha-tocopherol),licorice root (Glycyrrhiza uralensis), aloe vera, horseradish root,L-glutamine, natural marine lipid concentrate, ascorbic acid,antiscorbutic vitamin, rose hips, calcium ascorbate, cevitamic acid,citrus bioflavonoids complex, acerola, zinc or an effective saltthereof, Astragalus membranaceous, Astragalus mongolicus, membranousmilk vetch, milk vetch, mongolian milk, dong quai, huangqi, hunag qi,moringa and combinations thereof.

The formulation containing a pharmaceutical ingredient and anutraceutical ingredient is then administered in order to remedy one ofthe above-referenced maladies. Although these ingredients are preferred,other pharmaceutical and nutraceutical ingredients may be substituted intheir place.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS OF THE INVENTION

For the purposes of this specification, the word “pharmaceutical” refersto a material that is:

a) a synthetically produced bioactive compound, where no structurallyidentical, naturally produced analog to the synthetically producedbioactive compound exists; or

b) a biologically active compound derived from a living organism, wherethe biologically active compound is not a dietary supplement.

The pharmaceuticals utilized in this invention include the equivalentand alternative salts which may be formulated from the basepharmaceuticals and which achieve substantially the same effect as thepharmaceutical listed.

For the purposes of this specification, a “dietary supplement” isdefined as a product (other than tobacco) that bears or contains one ormore of the following dietary ingredients: a vitamin, a mineral, an herbor other botanical, an amino acid, a dietary substance for use by man tosupplement the diet by increasing the total daily intake of thatsubstance, or a concentrate, metabolite, constituent, extract, orcombinations of these ingredients.

The word “nutraceutical,” for the purposes of this application, refersto a food item, or a part of a food item, that offers medical healthbenefits, including prevention and/or treatment of disease. Moreparticularly, a nutraceutical is a material that is:

a) a dietary supplement containing a nutritive bioactive compound; or

b) a biologically active processed or unprocessed material derived froma plant, a fungus, an animal, or a portion thereof; where the precisecomposition of the biologically active processed or unprocessed materialmay be undetermined.

Examples of a biologically active processed material may include afinely chopped, powdered, pureed, or cooked material derived from plantor animal tissue, or an extract of plant or animal tissue.

Broadly, the inventive composition is a medicinal composition containinga pharmaceutical used for the treatment of a first predetermined ailmentor a symptom thereof, and a nutraceutical used for treatment of a secondpredetermined ailment or a symptom thereof. The pharmaceutical and thenutraceutical are mixed and compounded with a pharmaceuticallyacceptable base into a pharmaceutical dosage form.

The preferred pharmaceuticals include pain relieving and/oranti-inflammatory drugs, such as acetaminophen, non-steroidalanti-inflammatory drugs, and mixtures thereof. These non-steroidalanti-inflammatory drugs include diclophenac, fenflofenac; aspirin;indomethacin, sulindac, tolmetin, ibuprofen, ketoprofen, fenoprofen,flurbiprofen, naproxen, meclofenamic acid, flufenamic acid, piroxicam,tenoxicam, meloxicam, celicoxib, roficoxib, nabumetone, effective saltsthereof, derivatives thereof, and combinations thereof.

A second class of pharmaceuticals which may be used is theantihistamines. The antihistamines include astemizole, azatadine,brompheniramine, cetirizine, chlorpheniramine, clemastine,cyproheptadine, dexchlorpheniramine, dimenhydrinate, diphenhydramine,doxylamine, hydroxyzine, loratadine, phenindamine, terfenadine,tripelennamine, effective salts thereof, derivatives thereof, andmixtures thereof, with diphenhydramine and chlorpheniramine beingparticularly preferred.

A third class of pharmaceuticals which may be used is the decongestants.Particularly preferred decongestants include ephedrine, phenylephrine,phenylpropanolamine and pseudoephedrine, effective salts thereof,derivatives thereof, and mixtures thereof. The decongestants arecommonly used in combination with antihistamines.

Pharmaceuticals for use in treating acid reflux disease or gastriculcers may be used as a fourth class of drugs. The Histamine H₂-receptorantagonists Cimetidine, Famotidine, Nizatidine, and Ranitidine areparticularly useful for this purpose.

Expectorants such as Guaifenesin are also acceptable pharmaceuticals, asare cough suppressants such as dextromethorphan.

The therapeutic uses of the pharmaceuticals used in the presentinvention are well known and need no further explanation. Thenutraceuticals which may be used in the present invention have a varietyof medicinal uses which improve the efficacy of pharmaceuticals.

The immune boosters and/or anti-viral agents are a first class ofnutraceuticals. These agents are useful for accelerating wound-healingand improved immune function; and they include extracts from theconeflowers, or herbs of the genus Echinacea, such as Echinaceapurpurea, Echinacea angustfolia, Echinacea pillida, and mixturesthereof; extracts from herbs of the genus Sambuca, such as elderberries;and Goldenseal extracts. The coneflowers in particular are a popularherbal remedy used in the central United States, an area to which theyare indigenous. The coneflowers normally contain about 0.1% ofechinacoside, a caffeic acid glycoside, and echinacein, a complexisobutylamide. The extract derived from the roots contains varyingamounts of unsaturated alkyl ketones or isobutylamides. Goldenseal is animmune booster with antibiotic activity, and includes the compoundsberberine and hydrastine, which respectively stimulate bile secretionsand constrict peripheral blood vessels. Astragalus membranaceous,Astragalus mongolicus, and other herbs of the genus Astragalus are alsoeffective immune boosters in either their natural or processed forms.Astragalus stimulates development into of stem cells in the marrow andlymph tissue active immune cells. Zinc and its bioactive salts, such aszinc gluconate and zinc acetate, also act as immune boosters in thetreatment of the common cold.

Antioxidants are a second class of nutraceuticals. These antioxidantsinclude the natural, sulfur-containing amino acid allicin, which acts toincrease the level of antioxidant enzymes in the blood. Herbs or herbalextracts, such as garlic, which contain allicin are also effectiveantioxidants. The catechins, and the extracts of herbs such as green teacontaining catechins, are also effective antioxidants. Extracts of theimmune boosters Astragalus membranaceous, Astragalus mongolicus, andother herbs of the genus Astragalus also show antioxidant activity. Thebioflavonoids, such as quercetin, hesperidin, rutin, and mixturesthereof, are also effective as antioxidants. The primary beneficial roleof the bioflavonoids may be in protecting vitamin C from oxidation inthe body. This makes more vitamin C, or ascorbic acid, available for useby the body. Ascorbic acid, which is itself an important antioxidantnutraceutical, functions as a free radical scavenger that helps reduceoxidative stress and/or cell damage caused by free radicals.

Bioflavonoids such as quercetin are also effective anti-inflammatoryagents, and may be used as such in the inventive compositions.Anti-inflammatory herbal nutraceuticals and anti-inflammatorynutraceutical compounds derived from plants or herbs may also be used asanti-inflammatory agents in the inventive composition. These includebromolain, a proteolytic enzyme found in pineapple; teas and extracts ofstinging nettle; turmeric, extracts of turmeric, or curcumin, a yellowpigment isolated from turmeric.

Liver protectants are also effective nutraceuticals which may be used inthis invention. Silymarin, an extract from milk thistle seeds containingthree isomeric flavonolignans, is a particularly effective liverprotectant, and is useful in treatment of patients with AIDS. Milkthistle and its extracts also appear to exhibit some antioxidantactivity.

Another nutraceutical which is used in the present invention is ginger,derived from herbs of the genus Zingiber, such as Zingiber officinale,Zingiber capitatum and Zingiber zerumbet. This nutraceutical has beenfound to possess cardiotonic activity due to compounds such as gingeroland the related compound shogaol as well as providing benefits in thetreatment of dizziness, and vestibular disorders. Ginger is alsoeffective in the treatment of nausea and other stomach disorders.

Other nutraceuticals effective against stomach disorders are licoriceand its extracts, and aloe vera. Licorice stimulates the bile productionby the liver, and can relieve ulcers and stomach aches and lowercholesterol. Studies on animals indicate that aloe vera and extracts orjuices prepared therefrom help maintain a healthy stomach lining andassist in digestion. L-glutamine is also effective in treating digestivedisorders, as are juices containing L-glutamine. L-Glutamine helpsprotect the structural integrity of the bowels, making it useful fortreating ulcers and “leaky gut syndrome.”

Nutraceuticals which assist in rebuilding soft tissue structures,particularly in rebuilding cartilage, are useful in compositions fortreating the pain of arthritis and other joint disorders. Glucosamine,glucosamine sulfate, chondroitin, and chondroitin sulfate areparticularly useful for this purpose. Marine lipid complexes, omega 3fatty acid complexes, and fish oil are also known to be useful intreating pain associated with arthritis.

Nutraceuticals useful in treating migraine headaches include feverfewand Gingko biloba. The main active ingredient in feverfew is thesesquiterpene lactone parthenolide, which inhibits the secretion ofprostaglandins which in turn cause pain through vasospastic activity inthe blood vessels. Feverfew also exhibits anti-inflammatory properties.Fish oil, owing to its platelet-stabilizing and antivasospastic actions,may also be useful in treating migraine headaches. The herb Gingkobiloba also assists in treatment of migraines by stabilizing arteriesand improving blood circulation.

Wild cherry bark extracts have a sedative action on the cough reflex,making them effective nutraceutical components of cough suppressantformulations. Additionally, they are effective at soothing sore throatpain.

Although some of the sample nutraceuticals listed above have beendescribed as to their pharmacological effects, other nutraceuticals mayalso be utilized in the present invention and their effects are welldocumented in the scientific literature.

In a first embodiment, the invention relates to a pharmaceuticalcomposition for treating the common cold, flu, or symptoms associatedwith a cold or flu. Such symptoms include headache, muscle aches, fever,nasal congestion, coughing, and general fatigue. The compositionincludes a pharmaceutical which is effective against a cold or the flu,or at least one of their symptoms. An effective medication for treatinga cold, the flu, or a related symptom may be prepared by combining atleast one of the pain-relieving and/or anti-inflammatory,antihistaminic, and/or decongestant pharmaceuticals listed in Table 1with at least one of the immune-boosting, antioxidant, and/ or liverprotective nutraceuticals listed in Table 1, and compounding them into apharmaceutically acceptable dosage form.

TABLE 1 Preferred Ingredients of Pharmaceutical/NutraceuticalFormulations for Treating a Cold or the Flu Pain-Relieving and/or ImmuneBoosting and/or Anti-inflammatory Pharmaceuticals Anti-ViralNutraceuticals Acetaminophen Coneflower extracts Non-SteroidalAnti-inflammatory Drugs Elderberry extracts AntihistaminicPharmaceuticals Goldenseal extracts Diphenhydramine Zinc gluconateChlorpheniramine Zinc acetate Astemizole Zinc oxide AzatadineAntioxidant Nutraceuticals Cetirizine Garlic and its extracts ClemastineGreen tea and its extracts Cyproheptadine Astragalus extracts LoratadineGrapefruit seed extracts Terfenadine Vitamin C DecongestantPharmaceuticals Allicin Ephedrine Catechins Phenylephrine BioflavonoidsPhenylpropanolamine Liver Protectant Nutraceuticals Pseudoephedrine MilkThistle extracts

Particularly preferred formulations in accordance with the firstembodiment of the invention include pharmaceutical dosage formseffective against cold and/or flu which contain:

a) a pain-relieving and/or anti-inflammatory pharmaceutical agent incombination with at least one nutraceutical selected from the groupconsisting of immune boosters and/or anti-viral agents, antioxidants,and the liver protectant milk thistle;

b) an antihistaminic pharmaceutical agent in combination with at leastone nutraceutical selected from the group consisting of immune boostersand/or anti-viral agents and antioxidants;

c) a decongestant pharmaceutical agent in combination with at least onenutraceutical selected from the group consisting of immune boostersand/or anti-viral agents and antioxidants;

d) a mixture of a pain-relieving and/or anti-inflammatory pharmaceuticalagent and an antihistaminic pharmaceutical agent in combination with atleast one nutraceutical selected from the group consisting of immuneboosters and/or anti-viral agents, antioxidants, and the liverprotectant milk thistle;

e) a mixture of a pain-relieving and/or anti-inflammatory pharmaceuticalagent and a decongestant pharmaceutical agent in combination with atleast one nutraceutical selected from the group consisting of immuneboosters and/or anti-viral agents, antioxidants, and the liverprotectant milk thistle;

f) a mixture of a decongestant pharmaceutical agent and anantihistaminic pharmaceutical agent in combination with at least onenutraceutical selected from the group consisting of immune boostersand/or anti-viral agents, anti-inflammatory nutraceuticals, andantioxidants; and

g) a mixture of a pain-relieving and/or anti-inflammatory pharmaceuticalagent, a decongestant pharmaceutical agent, and an antihistaminicpharmaceutical agent in combination with at least one nutraceuticalselected from the group consisting of immune boosters and/or anti-viralagents, antioxidants, and the liver protectant milk thistle.

Preferably, the liver protectant milk thistle is only used as anutraceutical in compositions containing a pain-relieving and/oranti-inflammatory pharmaceutical agent; more preferably, the liverprotectant milk thistle is used as a nutraceutical in compositionscontaining acteaminophen.

In a second embodiment, the invention relates to a pharmaceuticalcomposition for suppressing coughs. An effective medication for treatingcoughs may be prepared by combining at least one of the coughsuppressant pharmaceuticals or the expectorant pharmaceuticals listed inTable 2 with at least one of the immune-boosting, antioxidant, coughreflex sedative, and/or liver protective nutraceuticals listed in Table2, and compounding them into a pharmaceutically acceptable dosage form.A decongestant pharmaceutical listed in Table 2 may optionally bepresent in the cough medication. It is also possible to prepare aneffective cough medication containing a decongestant pharmaceutical withno cough suppressant or expectorant pharmaceuticals present, if a coughreflex sedative such as wild cherry bark extract is included in theformulation.

TABLE 2 Preferred Ingredients of Cough SuppressantPharmaceutical/Nutraceutical Formulations Cough SuppressantPharmaceuticals Immune Boosting and/or Dextromethorphan Anti-ViralNutraceuticals Expectorant Pharmaceuticals Coneflower extractsGuaifenesin Elderberry extracts Decongestant Pharmaceuticals Goldensealextracts Ephedrine Zinc gluconate Phenylephrine Zinc acetatePhenylpropanolamine Zinc oxide Pseudoephedrine AntioxidantNutraceuticals Garlic and its extracts Green tea and its extractsAstragalus extracts Grapefruit seed extracts Vitamin C Allicin CatechinsBioflavonoids Liver Protectant Nutraceuticals Milk Thistle extractsNutraceuticals for Sedating the Cough Reflex Wild Cherry Extract

Particularly preferred formulations in accordance with the secondembodiment of the invention include cough suppressant pharmaceuticaldosage forms which contain:

a) a cough suppressing pharmaceutical agent in combination with at leastone nutraceutical selected from the group consisting of immune boostersand/or anti-viral agents, anti-oxidants and cough reflex sedatives;

b) an expectorant pharmaceutical agent in combination with at least onenutraceutical selected from the group consisting of immune boostersand/or anti-viral agents, anti-oxidants and cough reflex sedatives;

c) a mixture of a cough suppressing pharmaceutical agent and anexpectorant pharmaceutical agent in combination with at least onenutraceutical selected from the group consisting of immune boostersand/or anti-viral agents, anti-oxidants and cough reflex sedatives;

d) a mixture of a cough suppressing pharmaceutical agent and adecongestant pharmaceutical agent in combination with at least onenutraceutical selected from the group consisting of immune boostersand/or anti-viral agents, anti-oxidants and cough reflex sedatives;

e) a mixture of an expectorant pharmaceutical agent and a decongestantpharmaceutical agent in combination with at least one nutraceuticalselected from the group consisting of immune boosters and/or anti-viralagents, anti-oxidants and cough reflex sedatives;

f) a mixture of a cough suppressing pharmaceutical agent, an expectorantpharmaceutical agent, and a decongestant pharmaceutical agent incombination with at least one nutraceutical selected from the groupconsisting of immune boosters and/or anti-viral agents, anti-oxidantsand cough reflex sedatives; or

g) a decongestant, a nutraceutical which acts as a cough reflexsedative, and optionally at least one nutraceutical selected from thegroup consisting of immune boosters and/or anti-viral agents, andanti-oxidants.

In a third embodiment, the invention relates to a pharmaceuticalcomposition for treating the respiratory disorders resulting from sinuscongestion or from allergies. An effective medication for treatingallergies or sinus conditions may be prepared by combining at least oneof the antihistaminic pharmaceuticals and/or decongestantpharmaceuticals listed in Table 3 with at least one of theanti-inflammatory, antioxidant, and/ or liver protective nutraceuticalslisted in Table 3, and compounding them into a pharmaceuticallyacceptable dosage form.

TABLE 3 Preferred Ingredients of Pharmaceutical/NutraceuticalFormulations for Treating Allergies and/or Sinus Conditions DecongestantPharmaceuticals Anti-inflammatory Nutraceuticals Ephedrine BioflavonoidsPhenylephrine Curcumin Phenylpropanolamine Quercetin PseudoephedrineStinging nettle extracts Antihistaminic Pharmaceuticals Turmeric and itsextracts Diphenhydramine Bromolain Chlorpheniramine AntioxidantNutraceuticals Astemizole Garlic and its extracts Azatadine Green teaand its extracts Cetirizine Astragalus extracts Clemastine Grapefruitseed extracts Cyproheptadine Vitamin C Loratadine Allicin TerfenadineCatechins Bioflavonoids Liver Protectant Nutraceuticals Milk Thistleextracts

Particularly preferred formulations in accordance with the thirdembodiment of the invention include pharmaceutical dosage forms fortreating allergy and sinus conditions which contain:

a) a decongestant agent in combination with at least one nutraceuticalselected from the group consisting of anti-inflammatories, anti-oxidantsand liver protectants;

b) an antihistamine agent in combination with at least one nutraceuticalselected from the group consisting of anti-inflammatories, anti-oxidantsand liver protectants; or

c) a mixture of a decongestant agent and an antihistamine agent incombination with at least one nutraceutical selected from the groupconsisting of anti-inflammatories, anti-oxidants and liver protectants.

In a fourth embodiment, the invention relates to an analgesicpharmaceutical composition for relieving pain brought about by aninflammatory response. An effective medication for treating painconditions brought about by an inflammatory response, may be prepared bycombining at least one of the pain-relieving and/or anti-inflammatorypharmaceutical agents listed in Table 4 with at least one of theimmune-booster and/or anti-viral nutraceuticals, antioxidantnutraceuticals, joint relief nutraceuticals and liver protectantnutraceuticals listed in Table 4, and compounding them into apharmaceutically acceptable dosage form.

TABLE 4 Preferred Ingredients of Analgesic and/or Pain RelievingPharmaceutical/Nutraceutical Formulations Pain-Relieving and/or ImmuneBoosting and/or Anti-inflammatory Pharmaceuticals Anti-ViralNutraceuticals Acetaminophen Coneflower extracts diclophenac Elderberryextracts fenflofenac Goldenseal extracts aspirin Zinc gluconateindomethacin Zinc acetate sulindac Zinc oxide tolmetin AntioxidantNutraceuticals ibuprofen Garlic and its extracts ketoprofen Green teaand its extracts fenoprofen Astragalus extracts flurbiprofen Grapefruitseed extracts naproxen Vitamin C meclofenamic acid Allicin flufenamicacid Catechins piroxicam Bioflavonoids tenoxicam Liver ProtectantNutraceuticals meloxicam Milk Thistle extracts celicoxib Nutraceuticalsfor relief of Joint Pain roficoxib Glucosamine sulfate nabumetoneChondroitin sulfate

In a fifth embodiment, the invention relates to an pharmaceuticalcomposition for relieving migraine pain. An effective medication fortreating pain conditions may be prepared by combining at least one ofthe pain-relieving and/or anti-inflammatory pharmaceutical agents listedin Table 5 with at least one of the vascular dilating nutraceuticals,anti-nausea nutraceuticals, and liver protectant nutraceuticals listedin Table 5, and compounding them into a pharmaceutically acceptabledosage form.

TABLE 5 Preferred Ingredients of Pharmaceutical/NutraceuticalFormulations for Treating Migraine Headaches Pain-Relieving and/orNutraceutical Vascular Dilators Anti-inflammatory PharmaceuticalsFeverfew and its extracts Acetaminophen Gingko biloba and its extractsdiclophenac Omega 3 fatty acid complexes fenflofenac Marine LipidComplex aspirin Anti-nausea Nutraceuticals indomethacin Ginger and itsextracts sulindac Liver Protectant Nutraceuticals tolmetin Milk Thistleextracts ibuprofen ketoprofen fenoprofen flurbiprofen naproxenmeclofenamic acid flufenamic acid piroxicam tenoxicam meloxicamcelicoxib roficoxib nabumetone

In a sixth embodiment, the invention relates to an pharmaceuticalcomposition for treating acid reflux disease and/or heartburn. Aneffective medication for treating acid reflux may be prepared bycombining at least one of the pharmaceutical agents listed in Table 6with at least one of the nutraceuticals for treating stomach disordersand/or protecting the integrity of the gut or protecting the liverlisted in Table 6, and compounding them into a pharmaceuticallyacceptable dosage form.

TABLE 6 Preferred Ingredients of Pharmaceutical/NutraceuticalFormulations for Treating Acid Reflux Disease Acid-controllingPharmaceuticals Nutraceuticals Useful for Soothing Cimetidine StomachDisorders Famotidine Ginger and its extracts Nizatidine Licorice and itsextracts Ranitidine Aloe vera Nutraceuticals Useful for Protecting theGastric Mucosal Lining L-Glutamine Liver Protectant Nutraceuticals MilkThistle extracts

Formulations of the first six embodiments of the invention may beprepared in accordance with the standards set forth in the“Pharmaceutical Manufacturing Encyclopedia” by Marshall Sittig (NoyesPublications, 2^(nd) Edition, 1988). The invention also encompasses theaddition of one or more pharmaceutical additives commonly used in theformulation of pharmaceuticals and nutritional supplements as set forthin the “Handbook of Pharmaceutical Additives” by Michael Ash and IreneAsh (Gower Publishing, Limited, 1995). Such additives compriseexcipients, adjuvants, solvents, carriers, flavorants, stabilizers,binders and coatings. These allow for the formulation of the variousembodiments into tablets; capsules; orally-administered or injectableliquids, suspensions, or dispersions; powder; injectable liquids; andsuppositories

In a seventh embodiment, the invention relates to a nasal decongestantspray. An effective medication for treating nasal congestion may beprepared by combining at least one of the decongestant pharmaceuticalagents listed in Table 7 with at least one of the immune-boosting and orantioxidant nutraceuticals listed in Table 7, and combining them with aliquid vehicle. Preferably, the decongestant and the nutraceutical aredissolved or dispersed into an aqueous saline solution. The solution isthen packaged as a spray, which can be administered topically onto thenasal mucosa.

TABLE 7 Preferred Ingredients of Pharmaceutical/NutraceuticalFormulations for Use in Nasal Decongestant Sprays DecongestantPharmaceuticals Immune Boosting and/or Ephedrine Anti-ViralNutraceuticals Phenylephrine Coneflower extracts PhenylpropanolamineElderberry extracts Pseudoephedrine Goldenseal extracts Zinc gluconateZinc acetate Zinc oxide Antioxidant Nutraceuticals Garlic and itsextracts Green tea and its extracts Astragalus extracts Vitamin CAllicin Catechins Bioflavonoids

The following examples constitute some of the embodiments of theinvention as well as the preferred embodiments and the most preferredembodiments. The active ingredients specified in the illustrativeembodiments are stated in ranges which are suitable for carrying out theinvention.

Examples of formulations which demonstrate the present invention in someof its embodiments are provided below. Unless otherwise stated, herbalingredients are used in the form of dried extracts.

EXAMPLE 1

A solid composition comprising, Acetaminophen, in a range ofapproximately 60 mg to 1000 mg, in a preferred range of approximately200 mg to 750 mg, and in a most preferred range of approximately 350 mgto 550 mg, Diphenhydramine in a range of approximately 5 mg to 100 mg,in a preferred range of approximately 10 mg to 50 mg, and in a mostpreferred range of approximately 20 mg to 40 mg, Pseudoephedrine in arange of approximately 5 mg to 100 mg, in a preferred range ofapproximately 10 mg to 75 mg, and in a most preferred range ofapproximately 20 mg to 40 mg, Echinacea purpurea in a range ofapproximately 10 mg to 500 mg, in a preferred range of approximately 25mg to 200 mg, and in a most preferred range of approximately 50 mg to100 mg, Goldenseal in a range of approximately 50 mg to 200 mg, in apreferred range of approximately 75 mg to 150 mg, and in a mostpreferred range of approximately 80 mg to 120 mg, Elderberry (sambucol)in a range of approximately 50 mg to 250 mg, in a preferred range ofapproximately 75 mg to 175 mg, and in a most preferred range ofapproximately 100 mg to 150 mg, Garlic extract in a range ofapproximately 50 mg to 200 mg, in a preferred range of approximately 75mg to 150 mg, and in a most preferred range of approximately 80 mg to120 mg, Green tea extract in a range of approximately 50 mg to 200 mg,in a preferred range of approximately 75 mg to 150 mg, and in a mostpreferred range of approximately 80 mg to 120 mg, Astragalus in a rangeof approximately 50 mg to 250 mg, in a preferred range of approximately75 mg to 175 mg, and in a most preferred range of approximately 100 mgto 150 mg, Zinc gluconate in a range of approximately 0.1 mg to 15 mg,in a preferred range of approximately 0.5 mg to 10 mg, and in a mostpreferred range of approximately 1 mg to 7.5 mg, and Ascorbic acid in arange of approximately 50 mg to 1000 mg, in a preferred range ofapproximately 100 mg to 750 mg, and in a most preferred range ofapproximately 200 mg to 500 mg. This composition is administered to amammal, in need thereof, in the form of a capsule, for treating thesymptoms of a cold or flu every 4 to 6 hours to relieve pain anddiscomfort associated with a cold or flu and to provide immune systemstimulation. The potential for acetaminophen induced liver damage isreduced by the presence of Echinacea purpurea and Astragalus.

EXAMPLE 2

A composition comprising, Ibuprofen in a range of approximately 50 mg to500 mg, in a preferred range of approximately 100 mg to 350 mg, and in amost preferred range of approximately 125 mg to 250 mg, Chlorpheniraminein a range of approximately 0.1 mg to 10 mg, in a preferred range ofapproximately 0.5 mg to 7.5 mg, and in a most preferred range ofapproximately 1 mg to 3 mg, Pseudoephedrine in a range of approximately5 mg to 100 mg, in a preferred range of approximately 10 mg to 75 mg,and in a most preferred range of approximately 20 mg to 50 mg, Echinaceapurpurea in a range of approximately 10 mg to 500 mg, in a preferredrange of approximately 25 mg to 200 mg, and in a most preferred range ofapproximately 50 mg to 100 mg, Goldenseal in a range of approximately 50mg to 200 mg, in a preferred range of approximately 75 mg to 150 mg, andin a most preferred range of approximately 80 mg to 120 mg, Elderberry(sambucol) in a range of approximately 50 mg to 250 mg, in a preferredrange of approximately 75 mg to 175 mg, and in a most preferred range ofapproximately 100 mg to 150 mg, Garlic extract in a range ofapproximately 50 mg to 200 mg, in a preferred range of approximately 75mg to 150 mg, and in a most preferred range of approximately 80 mg to120 mg, Green tea extract in a range of approximately 50 mg to 200 mg,in a preferred range of approximately 75 mg to 150 mg, and in a mostpreferred range of approximately 80 mg to 120 mg, Astragalus in a rangeof approximately 50 mg to 250 mg, in a preferred range of approximately75 mg to 175 mg, and in a most preferred range of approximately 100 mgto 150 mg, Zinc gluconate in a range of approximately 0.1 mg to 15 mg,in a preferred range of approximately 0.5 mg to 10 mg, and in a mostpreferred range of approximately 1 mg to 7.5 mg, and Ascorbic acid in arange of approximately 50 mg to 1000 mg, in a preferred range ofapproximately 100 mg to 750 mg, and in a most preferred range ofapproximately 200 mg to 500 mg. This composition is administered to amammal, in a liquid form, for treating the symptoms of a cold or fluevery 4 to 6 hours to relieve pain and discomfort associated with a coldor flu and to provide immune system stimulation.

EXAMPLE 3

A composition comprising, Aspirin, in an approximate range of 80 mg to1000 mg, Pseudoephedrine HCl, in an approximate range of 2.5 mg to 240mg, Diphenhydramine HCl, in an approximate range of 6.25 mg to 1000 mg,an herb selected from the genus Echinacea, in an approximate range of100 mg to 1000 mg, Elderberry, in approximate range of 50 mg to 500 mg,Green tea, in an approximate range of 100 mg to 400 mg, vitamin C, in anapproximate range of 45 mg to 1000 mg, Zinc, in an approximate range of10 mg to 50 mg, and Astragalus, in an approximate range of 500 mg to1000 mg, are administered to a mammal, for treating the aches, pains anddiscomfort associated with a cold or flu as well as boosting the immunesystem.

EXAMPLE 4

A liquid composition comprising Guaifenesin in a range of approximately25 mg to 250 mg, in a preferred range of approximately 50 mg to 175 mg,and in a most preferred range of approximately 75 mg to 150 mg,Phenylpropanolamine hydrochloride in a range of approximately 2 mg to 25mg, in a preferred range of approximately 5 mg to 20 mg, and in a mostpreferred range of approximately 7.5 mg to 15 mg, Dextromethorphanhydrochloride in a range of approximately 1 mg to 20 mg, in a preferredrange of approximately 5 mg to 15 mg, and in a most preferred range ofapproximately 7.5 mg to 12.5 mg, Echinacea purpurea in a range ofapproximately 50 mg to 500 mg, in a preferred range of approximately 100mg to 350 mg, and in a most preferred range of approximately 150 mg to275 mg, Elderberry in a range of approximately 10 mg to 250 mg, in apreferred range of approximately 25 mg to 200 mg, and in a mostpreferred range of approximately 75 mg to 175 mg, Ascorbic acid in arange of approximately 50 mg to 1000 mg, in a preferred range ofapproximately 100 mg to 750 mg, and in a most preferred range ofapproximately 200 mg to 500 mg, wild cherry bark in a range ofapproximately 0.1 mg to 50 mg, in a preferred range of approximately 0.5mg to 25 mg, and in a most preferred range of approximately 1 mg to 15mg, and milk thistle in a range of approximately 10 mg to 100 mg, in apreferred range of approximately 20 mg to 75 mg, and in a most preferredrange of approximately 40 mg to 60 mg, is administered to a person inneed thereof in liquid form ranging from 2.5 ml to 10 ml, up to fourtimes daily, for treating coughing symptoms and having an expectoranteffect.

EXAMPLE 5

A composition comprising Phenylpropanolamine hydrochloride in a range ofapproximately 2 mg to 25 mg, in a preferred range of approximately 5 mgto 20 mg, and in a most preferred range of approximately 6.5 mg to 15mg, Dextromethorphan hydrochloride in a range of approximately 1 mg to20 mg, in a preferred range of approximately 2.5 mg to 15 mg, and in amost preferred range of approximately 5 mg to 10 mg, Echinacea purpureain a range of approximately 1 mg to 100 mg, in a preferred range ofapproximately 2.5 mg to 50 mg, and in a most preferred range ofapproximately 5 mg to 25 mg, Elderberry in a range of approximately 10mg to 150 mg, in a preferred range of approximately 25 mg to 125 mg, andin a most preferred range of approximately 50 mg to 100 mg, ascorbicacid in a range of approximately 50 mg to 1000 mg, in a preferred rangeof approximately 75 mg to 500 mg, and in a most preferred range ofapproximately 100 mg to 250 mg, and Wild cherry in a range ofapproximately 0.1 mg to 50 mg, in a preferred range of approximately 0.5mg to 25 mg, and in a most preferred range of approximately 1 mg to 15mg, is administered to a person in need thereof in liquid form, at adosage of between 2.5 ml to 10 ml, up to four time daily for treatingcoughing symptoms and having an expectorant effect.

EXAMPLE 6

A composition comprising Pseudoephedrine sulfate in a range ofapproximately 10 mg to 100 mg, in a preferred range of approximately 15mg to 75 mg, and in a most preferred range of approximately 25 mg to 50mg, Chlorphenriamine sulfate in a range of approximately 0.5 mg to 15mg, in a preferred range of approximately 1 mg to 10 mg, and in a mostpreferred range of approximately 2.5 mg to 7.5 mg, Quercetin in a rangeof approximately 50 mg to 1000 mg, in a preferred range of approximately75 mg to 500 mg, and in a most preferred range of approximately 100 mgto 250 mg, Stinging nettles in a powder form in a range of approximately50 mg to 1000 mg, in a preferred range of approximately 75 mg to 500 mg,and in a most preferred range of approximately 100 mg to 250 mg,Elderberry in a range of approximately 50 mg to 1000 mg, in a preferredrange of approximately 75 mg to 500 mg, and in a most preferred range ofapproximately 100 mg to 250 mg, Goldenseal in a range of approximately50 mg to 1000 mg, in a preferred range of approximately 75 mg to 500 mg,and in a most preferred range of approximately 100 mg to 250 mg,Curcumin in a range of approximately 50 mg to 1000 mg, in a preferredrange of approximately 75 mg to 500 mg, and in a most preferred range ofapproximately 100 mg to 250 mg, and Ascorbic acid in a range ofapproximately 50 mg to 1000 mg, in a preferred range of approximately 75mg to 500 mg, and in a most preferred range of approximately 100 mg to250 mg, is administered to a person suffering from sinus and allergydiscomfort, in the form of a tablet or capsule every 4 to 6 hours forclearing the nasal passages and relieving sinus pressure as well asproviding an immune boosting effect.

EXAMPLE 7

A composition comprising Pseudoephedrine sulfate in a range ofapproximately 10 mg to 100 mg, in a preferred range of approximately 15mg to 75 mg, and in a most preferred range of approximately 25 mg to 50mg, Diphenhydramine sulfate in a range of approximately 5 mg to 50 mg,in a preferred range of approximately 10 mg to 40 mg, and in a mostpreferred range of approximately 15 mg to 30 mg, Quercetin in a range ofapproximately 50 mg to 1000 mg, in a preferred range of approximately 75mg to 500 mg, and in a most preferred range of approximately 100 mg to250 mg, Stinging nettles in a powder form in a range of approximately 50mg to 1000 mg, in a preferred range of approximately 75 mg to 500 mg,and in a most preferred range of approximately 100 mg to 250 mg,Elderberry in a range of approximately 50 mg to 1000 mg, in a preferredrange of approximately 75 mg to 500 mg, and in a most preferred range ofapproximately 100 mg to 250 mg, Goldenseal in a range of approximately50 mg to 1000 mg, in a preferred range of approximately 75 mg to 500 mg,and in a most preferred range of approximately 100 mg to 250 mg,Curcumin in a range of approximately 50 mg to 1000 mg, in a preferredrange of approximately 75 mg to 500 mg, and in a most preferred range ofapproximately 100 mg to 250 mg, and Ascorbic acid in a range ofapproximately 50 mg to 1000 mg, in a preferred range of approximately 75mg to 500 mg, and in a most preferred range of approximately 100 mg to250 mg, is administered to a person suffering from sinus and allergydiscomfort, in the form of a liquid, tablet or capsule every 4 to 6hours to relieve sinus pressure, clear nasal passages and provide animmune boosting effect.

EXAMPLE 8

A composition comprising Acetaminophen in a range of approximately 50 mgto 1000 mg, in a preferred range of approximately 75 mg to 750 mg, andin a most preferred range of approximately 100 mg to 650 mg, Bromelainin a range of approximately 50 mg to 1000 mg, in a preferred range ofapproximately 75 mg to 500 mg, and in a most preferred range ofapproximately 100 mg to 250 mg, Curcumin in a range of approximately 50mg to 1000 mg, in a preferred range of approximately 75 mg to 500 mg,and in a most preferred range of approximately 100 mg to 250 mg,Ascorbic acid in a range of approximately 50 mg to 1000 mg, in apreferred range of approximately 75 mg to 750 mg, and in a mostpreferred range of approximately 100 mg to 500 mg, multiple pancreaticenzymes in a range of approximately 50 mg to 1000 mg, in a preferredrange of approximately 75 mg to 500 mg, and in a most preferred range ofapproximately 100 mg to 250 mg, and primrose oil in a range ofapproximately 50 mg to 1000 mg, in a preferred range of approximately 75mg to 500 mg, and in a most preferred range of approximately 100 mg to350 mg is administered to a human in a tablet form, every 4 to 6 hoursin order to bring about pain relief, promote the healing of injuredtissues and provide an antioxidant effect.

EXAMPLE 9

A composition comprising Aspirin in a range of approximately 50 mg to1000 mg, in a preferred range of approximately 100 mg to 750 mg, and ina most preferred range of approximately 250 mg to 600 mg, Bromelain in arange of approximately 50 mg to 1000 mg, in a preferred range ofapproximately 75 mg to 500 mg, and in a most preferred range ofapproximately 100 mg to 250 mg, Curcumin in a range of approximately 50mg to 1000 mg, in a preferred range of approximately 75 mg to 500 mg,and in a most preferred range of approximately 100 mg to 250 mg,Ascorbic acid in a range of approximately 50 mg to 1000 mg, in apreferred range of approximately 75 mg to 750 mg, and in a mostpreferred range of approximately 100 mg to 500 mg, multiple pancreaticenzymes in a range of approximately 50 mg to 1000 mg, in a preferredrange of approximately 75 mg to 500 mg, and in a most preferred range ofapproximately 100 mg to 250 mg, and primrose oil in a range ofapproximately 50 mg to 1000 mg, in a preferred range of approximately 75mg to 500 mg, and in a most preferred range of approximately 100 mg to350 mg is administered to a human in a tablet form, every 4 to 6 hoursin order to bring about pain relief, repair injured tissues and provideand antioxidant effect.

EXAMPLE 10

A composition comprising Ibuprofen in a range of approximately 50 mg to500 mg, in a preferred range of approximately 75 mg to 350 mg, and in amost preferred range of approximately 100 mg to 250 mg, Bromelain in arange of approximately 50 mg to 1000 mg, in a preferred range ofapproximately 75 mg to 500 mg, and in a most preferred range ofapproximately 100 mg to 250 mg, Curcumin in a range of approximately 50mg to 1000 mg, in a preferred range of approximately 75 mg to 500 mg,and in a most preferred range of approximately 100 mg to 250 mg,Ascorbic acid in a range of approximately 50 mg to 1000 mg, in apreferred range of approximately 75 mg to 750 mg, and in a mostpreferred range of approximately 100 mg to 500 mg, multiple pancreaticenzymes in a range of approximately 50 mg to 1000 mg, in a preferredrange of approximately 75 mg to 500 mg, and in a most preferred range ofapproximately 100 mg to 250 mg, and primrose oil in a range ofapproximately 50 mg to 1000 mg, in a preferred range of approximately 75mg to 500 mg, and in a most preferred range of approximately 100 mg to350 mg is administered to a human in a tablet form, every 4 to 6 hoursin order to bring about pain relief and repair injured tissues.

EXAMPLE 11

A composition comprising Ibuprofen in a range of approximately 50 mg to500 mg, in a preferred range of approximately 75 mg to 350 mg, and in amost preferred range of approximately 100 mg to 250 mg, Feverfew(Tanacetum parthenium) in a range of approximately 50 mg to 500 mg, in apreferred range of approximately 75 mg to 350 mg, and in a mostpreferred range of approximately 100 mg to 250 mg, Ginger root (Zingiberofficinale) in a range of approximately 10 mg to 500 mg, in a preferredrange of approximately 25 mg to 350 mg, and in a most preferred range ofapproximately 50 mg to 150 mg, Natural marine lipid concentrate in arange of approximately 500 mg to 1500 mg, in a preferred range ofapproximately 750 mg to 1250 mg, and in a most preferred range ofapproximately 950 mg to 1100 mg, Eicosapentaenoic acid in a range ofapproximately 50 mg to 300 mg, in a preferred range of approximately 75mg to 250 mg, and in a most preferred range of approximately 100 mg to200 mg, Docosahexaeonic acid in a range of approximately 50 mg to 250mg, in a preferred range of approximately 75 mg to 200 mg, and in a mostpreferred range of approximately 100 mg to 150 mg, is administered to aperson suffering from the effects of a migraine headache, in the form ofa capsule, every 4 to 6 hours, to treat pain and relieve migrainesymptoms.

EXAMPLE 12

Between 2.5 ml and 10 ml of a composition comprising Ranitidine in arange of approximately 10 mg to 200 mg, in a preferred range ofapproximately 25 mg to 150 mg, and in a most preferred range ofapproximately 50 mg to 100 mg, Ginger root in a range of approximately50 mg to 500 mg, in a preferred range of approximately 75 mg to 350 mg,and in a most preferred range of approximately 100 mg to 300 mg,Licorice root (Glycyrrhiza uralensis) in a range of approximately 50 mgto 500 mg, in a preferred range of approximately 75 mg to 350 mg, and ina most preferred range of approximately 100 mg to 250 mg, aloe veraextract in a range of approximately 5 mg to 100 mg, in a preferred rangeof approximately 10 mg to 75 mg, and in a most preferred range ofapproximately 15 mg to 35 mg, L-Glutamine in a range of approximately250 mg to 1000 mg, in a preferred range of approximately 350 mg to 750mg, and in a most preferred range of approximately 450 mg to 550 mg, andHorseradish root in a range of approximately 50 mg to 500 mg, in apreferred range of approximately 75 mg to 350 mg, and in a mostpreferred range of approximately 100 mg to 250 mg, is administered to aperson suffering from indigestion, in liquid form up to four times dailyto serve as a histamine antagonist and reduce the symptoms ofindigestion.

EXAMPLE 13

Between 5 ml and 10 ml of a composition comprising Cimetidine in a rangeof approximately 50 mg to 300 mg, in a preferred range of approximately75 mg to 250 mg, and in a most preferred range of approximately 100 mgto 200 mg, Ginger root in a range of approximately 50 mg to 500 mg, in apreferred range of approximately 75 mg to 350 mg, and in a mostpreferred range of approximately 100 mg to 300 mg, Licorice root(Glycyrrhiza uralensis) in a range of approximately 50 mg to 500 mg, ina preferred range of approximately 75 mg to 350 mg, and in a mostpreferred range of approximately 100 mg to 250 mg, aloe vera extract ina range of approximately 5 mg to 100 mg, in a preferred range ofapproximately 10 mg to 75 mg, and in a most preferred range ofapproximately 15 mg to 35 mg, L-Glutamine in a range of approximately250 mg to 1000 mg, in a preferred range of approximately 350 mg to 750mg, and in a most preferred range of approximately 450 mg to 550 mg, andHorseradish root in a range of approximately 50 mg to 500 mg, in apreferred range of approximately 75 mg to 350 mg, and in a mostpreferred range of approximately 100 mg to 250 mg, is administered to aperson suffering from indigestion, in liquid form up to four times dailyto prevent gastrointestinal distress.

EXAMPLE 14

A composition comprising phenylephrine hydrochloride (1%), Echinaceapurpurea in an approximate range of 50 mg to 500 mg, in a preferredrange of approximately 100 mg to 350 mg, and in a most preferred rangeof approximately 150 mg to 250 mg, elderberry in an approximate range of50 mg to 500 mg, in a preferred range of approximately 100 mg to 300 mg,and in a most preferred range of approximately 150 mg to 250 mg, Zincgluconate in an approximate range of 2.5 mg to 30 mg, in a preferredrange of approximately 5 mg to 25 mg, and in a most preferred range ofapproximately 10 mg to 20 mg, sodium ascorbate (1.5%) and grapefruitseed extract (0.10%), is administered to a person suffering from thesymptoms of a cold and flu in the form of 2 sprays up to four timesdaily to prevent sinus congestion and boost the immune system.

EXAMPLE 15

A composition comprising Echinacea purpurea in an approximate range of50 mg to 500 mg, in a preferred range of approximately 100 mg to 350 mg,and in a most preferred range of approximately 150 mg to 250 mg,elderberry in an approximate range of 50 mg to 500 mg, in a preferredrange of approximately 100 mg to 300 mg, and in a most preferred rangeof approximately 150 mg to 250 mg, Zinc gluconate in an approximaterange of 2.5 mg to 30 mg, in a preferred range of approximately 5 mg to25 mg, and in a most preferred range of approximately 10 mg to 20 mg,sodium ascorbate (1.5%), grapefruit seed extract (0.10%) and sodiumchloride (0.65%), is administered to a person suffering from nasal andsinus discomfort in the form of a 2 to 3 sprays up to four times dailyto relieve sinus congestion and provide and immune system boost.

Although the present invention has been described in detail withparticular reference to preferred embodiments thereof, it should beunderstood that the invention is capable of other different embodiments,and its details are capable of modifications in various obviousrespects. As is readily apparent to those skilled in the art, variationsand modifications can be affected while remaining within the spirit andscope of the invention. Accordingly, the foregoing disclosure,description, and figures are for illustrative purposes only, and do notin any way limit the invention, which is defined only by the claims.

What is claimed is:
 1. A medicinal composition comprising: at least onepharmaceutical; at least one nutraceutical; and a pharmaceuticallyacceptable base; wherein at least one of the pharmaceutical and thenutraceutical treats an immune response of the respiratory system, saidimmune response of the respiratory system causing a coughing reflex; andwherein the pharmaceutical comprises an effective amount of a coughsuppressant agent; and the nutraceutical comprises an effective amountof an immune boosting agent.
 2. A composition according to claim 1,wherein the cough suppressant agent comprises dextromethorphan.
 3. Acomposition according to claim 1, wherein the immune booster comprisesat least one nutraceutical selected from a group consisting of the groupzinc and effective salts thereof, at least one herb selected from agroup consisting of herbs of the genus Echinacea, at least one herbselected from a group consisting of herbs of the genus Sambucus,Goldenseal, and mixtures thereof.
 4. A composition according to claim 1,further comprising at least one additive selected from the groupconsisting of: a) an antioxidant; b) an expectorant; c) a decongestant;d) a liver protectant; and e) a cough reflex sedating agent.
 5. Acomposition according to claim 1, further comprising an antioxidantselected from a group consisting of at least one bioflavonoid, at leastone herbal extract containing at least one bioflavonoid, ascorbic acidand pharmaceutically effective salts and derivatives thereof, garlic andextracts thereof, green tea and its extracts, at least one herb selectedfrom a group consisting of herbs of the genus Astragalus, andcombinations thereof.
 6. A composition according to claim 1, furthercomprising an expectorant comprising guaifenesin.
 7. A compositionaccording to claim 1, further comprising a decongestant selected from agroup consisting of phenylpropanolamine, pseudoephedrine, ephedrine,phenylephrine, naphazoline, oxymetazoline, tetrahydrozoline,xylometazoline, propylhexedrine, L-desoxyephedrine, effective saltsthereof and combinations thereof.
 8. A composition according to claim 1,further comprising a liver protectant comprising milk thistle.
 9. Acomposition according to claim 1, further comprising a cough reflexsedating agent comprising wild cherry bark, extracts thereof andcombinations thereof.
 10. A composition according to claim 1, whereinthe cough suppressant comprises dextromethorphan and the immune boostercomprises zinc and effective salts thereof.
 11. A composition accordingto claim 1, wherein the cough suppressant comprises dextromethorphan andthe immune booster comprises at least one herb selected from a groupconsisting of herbs of the genus Echinacea.
 12. A composition accordingto claim 1, wherein the cough suppressant comprises dextromethorphan andthe immune booster comprises at least one herb selected from a groupconsisting of herbs of the genus Sambucus.
 13. A composition accordingto claim 1, wherein the cough suppressant comprises dextromethorphan andthe immune booster comprises Goldenseal.
 14. A method of treating acough, comprising: at least one pharmaceutical; at least onenutraceutical; and a pharmaceutically acceptable base; wherein at leastone of the pharmaceutical and the nutraceutical treats an immuneresponse of the respiratory system, said immune response of therespiratory system causing a coughing reflex; and wherein thepharmaceutical comprises an effective amount of a cough suppressantagent; and the nutraceutical comprises an effective amount of an immunebooster.
 15. A method according to claim 14, wherein the coughsuppressant agent comprises dextromethorphan.
 16. A method according toclaim 14, wherein the immune booster comprises at least onenutraceutical selected from a group consisting of the group zinc andeffective salts thereof, at least one herb selected from a groupconsisting of herbs of the genus Echinacea, at least one herb selectedfrom a group consisting of herbs of the genus Sambucus, Goldenseal, andmixtures thereof.
 17. A method according to claim 14, further comprisingat least one additive selected from the group consisting of: a) anantioxidant; b) an expectorant; c) a decongestant; d) a liverprotectant; and e) a cough reflex sedating agent.
 18. A method accordingto claim 14, further comprising an antioxidant selected from a groupconsisting of at least one bioflavonoid, at least one herbal extractcontaining at least one bioflavonoid, ascorbic acid and pharmaceuticallyeffective salts and derivatives thereof, garlic and extracts thereof,green tea and its extracts, at least one herb selected from the groupconsisting of herbs of the genus Astragalus, and combinations thereof.19. A method according to claim 14, further comprising an expectorantcomprising guaifenesin.
 20. A method according to claim 14, furthercomprising a decongestant selected from a group consisting ofphenylpropanolamine, pseudoephedrine, ephedrine, phenylephrine,naphazoline, oxymetazoline, tetrahydrozoline, xylometazoline,propylhexedrine, L-desoxyephedrine, effective salts thereof andcombinations thereof.
 21. A method according to claim 14, furthercomprising a liver protectant comprising milk thistle.
 22. A methodaccording to claim 14, further comprising a cough reflex sedating agentcomprising wild cherry bark, extracts thereof and combinations thereof.23. A method according to claim 14, wherein the cough suppressantcomprises dextromethorphan and the immune booster comprises zinc andeffective salts thereof.
 24. A method according to claim 14, wherein thecough suppressant comprises dextromethorphan and the immune boostercomprises at least one herb selected from a group consisting of herbs ofthe genus Echinacea.
 25. A method according to claim 14, wherein thecough suppressant comprises dextromethorphan and the immune boostercomprises at least one herb selected from a group consisting of herbs ofthe genus Sambucus.
 26. A method according to claim 14, wherein thecough suppressant comprises dextromethorphan and the immune boostercomprises Goldenseal.